Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ: SRPT )

116.09 -0.70 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Insiders Are Buying These 2 Stocks
Insider buying in both Loews (NYSE: L) and Sarepta (NASDAQ: SRPT) suggests a positive outlook for these stocks, potentially influencing investor sentiment. 
Via MarketBeat
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
NASDAQ:SRPT Shareholder Notice: Investigation over Possible Wrongdoing at Sarepta Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 06/02/2023 -- An investigation was announced concerning possible breaches of fiduciary duties by certain directors at Sarepta Therapeutics, Inc. 
Via SBWire
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)
Recent events surrounding Sarepta Therapeutics highlights the unpredictability of the biotech industry and its appropriateness solely for high-risk investors. 
Via MarketBeat
Exposures Product Safety
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
From Sarepta Therapeutics, Inc.
Via Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock. 
Via MarketBeat
Exposures Product Safety
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shareholder Notice: Investigation over Potential Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 04/10/2023 -- Sarepta Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
From Sarepta Therapeutics, Inc.
Via Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.